Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

2P - Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Edouard Auclin

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

E. Auclin1, P. Vuagnat2, C. Smolenschi2, J. Taieb3, J. Adeva Alfonso4

Author affiliations

  • 1 Hopital Européen Georges Pompidou, Paris/FR
  • 2 Institut Gustave Roussy, Villejuif/FR
  • 3 Hopital European George Pompidou, Paris/FR
  • 4 University Hospital 12 De Octubre, Madrid/ES
More

Abstract 2P

Background

MSI-H/dMMR is considered the first predictive marker of efficacy for ICIs with tissue/site-agnostic approval. However, around 39% of cases are refractory and no additional biomarker has been identified. We explored the prognostic value of pretreatment LIPI in MSI-H/dMMR patients (pts) treated with ICI, particularly to identify the fast-progressors (FP).

Methods

Multicenter retrospective study of pts with metastatic MSI-H/dMMR tumors treated with ICIs from Apr2014 to May2019. Biological and clinical data were collected; LIPI was calculated based on dNLR [neutrophils/leucocytes-neutrophils]>3 + LDH>Upper Limit of Normality (ULN), as reported. LIPI groups were: good (0 factor), intermediate (interm.; one factor) and poor (2 factors). Primary endpoint was overall survival (OS), including the FP (OS < 3 months); secondary endpoints were progression free survival (PFS).

Results

A total of 151 pts were treated, mainly female (59%), median age of 64y, with performance status (PS) >1 (68%), and sporadic dMMR status (68%). ICI was the 1st or 2nd line in 59%. The most frequent tumors types were gastrointestinal (66%) and gynecological (22%). LIPI groups were distributed as follows: good n=67 (47%), interm. n=62 (43%), poor n=14 (10%). The median (m) follow up was 32 months (m.). 24m OS rates were 71.1%, 54.2% and 14.3% for good, interm and poor risk groups, respectively (P<0.0001). After adjustment on tumor site, metastatic sites and PS, LIPI remains independently associated with OS (HR poor: 3.2, 95%CI:1.3-7.9, P=0.03). Overall, the FP rate was 16%; up to 35.7% in poor LIPI group vs. 7.5% in good LIPI (P=0.02). The odds ratio for FP event among the poor group was 6.9 [95%CI: 1.7-28.6; P=0.01]. Overall, mPFS was 10.5m. (7.1-35.1); by LIPI groups: 20.9m. (8.4-NR) for good, 9.9m. (2.8-NR) for interm. and 2.3m. (1.8-NR) for the poor group (P<0.0001).

Conclusions

LIPI identifies dMMR pts that do not benefit from ICI treatment, particularly the fast-progressors. It should be included as stratification factor for future trials.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

E. Auclin: Travel/Accommodation/Expenses: Mundipharma; Honoraria (self): Sanofi Genzymes. J. Taieb: Honoraria (self): Merck, Roche, Amgen, Lilly, Sanofi, Samsung, MSD, Servier, Celgene, Pierre Fabre; Advisory/Consultancy: Roche, Merck KGaA, Amgen, Lilly, MSD, Servier, Pierre Fabre, Sanofi, Samsung; Speaker Bureau/Expert testimony: Servier, Amgen, Roche, Sanofi, Merck, Lilly, Pierre Fabre. B. Besse: Research grant/Funding (institution): Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar. C. Massard: Advisory/Consultancy: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. L. Mezquita: Research grant/Funding (self): Bristol Myers Squibb, Boehringer Ingelheim, Amgen; Advisory/Consultancy: Roche Diagnostics, Takeda; Honoraria (self): Bristol Myers Squibb, Tecnofarma, Roche; Travel/Accommodation/Expenses: Roche; Non-remunerated activity/ies: AstraZeneca. A. Hollebecque: Advisory/Consultancy: Gritstone Oncology, Eisai Co., Ltd., Amgen, Servier and Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.